Document is current
Any future updates will be listed below
-
Authors
Ferrier, Graham https://orcid.org/0009-0006-1760-4697
Filipovic, Aleksandra
Wasan, Harpreet
di Pietro, Alessandra
Mittal, Deepali
Kamath, Geetanjali
Kharawala, Saifuddin
Mehmud, Faisal
-
Funding
Funding for this research was provided by:
Pfizer Inc. | Pfizer Foundation
- License Information
-
More Information
Article History
Received: 27 August 2024
Revised: 9 April 2025
Accepted: 15 April 2025
First Online: 30 April 2025
Competing interests
: Graham Ferrier and Faisal Mehmud are employed by Pfizer at the time of review and writing of the manuscript. Alessandra di Pietro is employed by Pfizer at the time of review and writing of the manuscript, and also owns stocks as part of her compensation. Deepali Mittal, Geetanjali Kamath, and Saifuddin Kharawala are employees of Bridge Medical Consulting, commissioned by Pfizer to carry out this literature review. Harpreet Wasan has acted on advisory boards or as an invited speaker or has attended meetings for Servier, Pierre Fabre, Incyte, Bayer, Pfizer, Zymeworks, Merck KGaA, Taiho, Seagen, Exact therapeutics, Takeda (Hutchinson Med), Amgen, Roche/Genentech/ FM, SIRTEX Medical, Erytech Pharma, BMS (Celgene), and BTG; has acted in a consultancy or advisory capacity for NICE/BSI expert Takeda, Bayer, Pierre Fabre, ONCOSIL, Incyte, Celgene, Oaktree life sciences; has served on Global Trials committees for Pfizer (Array); Zymeworks, Boehringer Ingelheim (DMC), SIRTEX, Merck KGaA, ARCAD (Pancreas Academic); and has received research funding from MSD, Merck Serono, Pfizer, and Sirtex. Aleksandra Filipovic has no competing interests.
